Suppression of RelB-mediated manganese superoxide dismutase expression reveals a primary mechanism for radiosensitization effect of 1α,25-dihydroxyvitamin D3 in prostate cancer cells

Molecular Cancer Therapeutics

Volumn 6, Issue 7, 2007, Pages 2048-2056

  Xu, Yong ^a   Fang, Fang ^b   St Clair, Daret K ^a   Josson, Sajni ^a   Sompol, Pradoldej ^a   Spasojevic, Ivan ^c   St Clair, William H ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; MANGANESE SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTOR RELB; VITAMIN D RECEPTOR;

ANTIOXIDANT RESPONSIVE ELEMENT; ARTICLE; CANCER CELL; CANCER RADIOTHERAPY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME REPRESSION; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; IONIZING RADIATION; LOW DRUG DOSE; MITOCHONDRION; PRIORITY JOURNAL; PROSTATE CARCINOMA; RADIOSENSITIVITY;

ANTIOXIDANTS; HUMANS; MALE; PROSTATIC NEOPLASMS; RADIATION TOLERANCE; RNA, SMALL INTERFERING; SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTOR RELB; VITAMIN D;

EID: 34447308768     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0700     Document Type: Article

References (50)

1. Gronberg H. Prostate cancer epidemiology. Lancet 2003;361:859-64.
2. Santen R. Clinical review 37: endocrine treatment of prostate cancer. J Clin Endocrinol Metab 1992;75:685-9.
3. Schwartz GG, Hulka BS. Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res 1990;10:1307-11.
4. John EM, Schwartz GG, Koo J, et al. Sun exposure, vitamin D receptor gene polymorphisms, and risk of advanced prostate cancer. Cancer Res 2005;65:5470-9.
5. Mehta RG, Mehta RR. Review, vitamin D and cancer. J Nutr Biochem 2002;13:252-64.
6. Stewart LV, Weigel NL. Vitamin D and prostate cancer. Exp Biol Med 2004;229:277-84.
7. 3. Cancer Res 1992;52:515-20.
8. Blutt SE, Polek TC, Stewart LV, et al. A calcitriol analogue, EB1089, inhibits the growth of LNCaP tumors in nude mice. Cancer Res 2000;60:779-82.
9. Skowronski RJ, Peehl DM, Feldman D. Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology 1993;132:1952-60.
10. 3 in androgen-responsive prostate cancer LNCaP cells. Cancer Res 2005;65:4762-8.
11. 3 in prostate cancer. Mol Cancer Ther 2002;1:667-77.
12. Carlberg C, Bendik I, Wyss A, et al. Two nuclear signalling pathways for vitamin D. Nature 1993;361:657-60.
13. Guzey M, Luo J, Getzenberg RH. Vitamin D3 modulated gene expression patterns in human primary normal and cancer prostate cells. J Cell Biochem 2004;93:271-85.
14. Bao BY, Hu YC, Ting HJ, Lee YF. Androgen signaling is required for the vitamin D-mediated growth inhibition in human prostate cancer cells. Oncogene 2004;23:3350-60.
15. 1 to S progression in LNCaP prostate cancer cells through p27Kip1 stabilization and Cdk2 mislocalization to the cytoplasm. J Biol Chem 2003;278:46862-8.
16. 1 accumulation or apoptosis of LNCaP prostate cancer cells. Endocrinology 2003;144:50-60.
17. 3. Nucleic Acids Res 2005;33:5521-32.
18. Nonn L, Peng L, Feldman D, Peehl DM. Inhibition of p38 by vitamin D reduces interleukin-6 production in normal prostate cells via mitogen-activated protein kinase phosphatase 5: implications for prostate cancer prevention by vitamin D. Cancer Res 2006;66:4516-24.
19. Kimura K, Bowen C, Spiegel S, Gelmann EP. Tumor necrosis factor-α sensitizes prostate cancer cells to γ-irradiation-induced apoptosis. Cancer Res 1999;59:1606-14.
20. Criswell T, Leskov K, Miyamoto S, et al. Transcription factors activated in mammalian cells after clinically relevant doses of ionizing radiation. Oncogene 2003;22:5813-27.
21. Magne N, Toillon RA, Bottero V, et al. NF-κB modulation and ionizing radiation: mechanisms and future directions for cancer treatment. Cancer Lett 2006;231:158-68.
22. Findley HW, Gu L, Yeager AM, Zhou M. Expression and regulation of Bcl-2, Bcl-xl, and Bax correlate with p53 status and sensitivity to apoptosis in childhood acute lymphoblastic leukemia. Blood 1997;89:2986-93.
23. Lee JU, Hosotani R, Wada M, et al. Role of Bcl-2 family proteins (Bax, Bcl-2, and Bcl-X) on cellular susceptibility to radiation in pancreatic cancer cells. Eur J Cancer 1999;35:1374-80.
24. Su ZZ, Lebedeva IV, Sarkar D, et al. Ionizing radiation enhances therapeutic activity of mda-7/IL-24: overcoming radiation- and mda-7/IL-24-resistance in prostate cancer cells overexpressing the antiapoptotic proteins bcl-xL or bcl-2. Oncogene 2006;25:2339-48.
25. Ghosh S, Karin M. Missing pieces in the NF-κB puzzle. Cell 2002;109:81-96.
26. Lessard L, Begin LR, Gleave ME, et al. Nuclear localisation of nuclear factor-κB transcription factors in prostate cancer: an immunohistochemical study. Br J Cancer 2005;93:1019-23.
27. Josson S, Xu Y, Fang F, et al. RelB regulates manganese superoxide dismutase gene and resistance to ionizing radiation of prostate cancer cells. Oncogene 2006;25:1554-9.
28. Xu Y, Kiningham KK, Devalaraja MN, et al. An intronic NF-κB element is essential for induction of the human manganese superoxide dismutase gene by tumor necrosis factor-α and interleukin-1β. DNA Cell Biol 1999;18:709-22.
29. Xu Y, Porntadavity S, St Clair DK. Transcriptional regulation of the human manganese superoxide dismutase gene: the role of specificity protein 1 (Sp1) and activating protein-2 (AP-2). Biochem J 2002;362:401-12.
30. 3. Endocrinology 1995;136:20-6.
31. 3 by suppressing 24-hydroxylase expression in LNCaP cells. J Steroid Biochem Mol Biol 2006;99:44-9.
32. Aggarwal BB. Nuclear factor-κB: the enemy within. Cancer Cell 2004;6:203-8.
33. Karin M. Nuclear factor-κB in cancer development and progression. Nature 2006;44:431-6.
34. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB. J Clin Invest 2001;107:241-6.
35. Guo J, Verma UN, Gaynor RB, et al. Enhanced chemosensitivity to irinotecan by RNA interference-mediated down-regulation of the nuclear factor-κB p65 subunit. Clin Cancer Res 2004;10:3333-41.
36. Lin A, Karin M. NF-κB in cancer: a marked target. Semin Cancer Biol 2003;13:107-14.
37. Egan LJ, Eckmann L, Greten FR, et al. IκB-kinaseβ-dependent NF-κB activation provides radioprotection to the intestinal epithelium. Proc Natl Acad Sci U S A 2004;101:2452-7.
38. Luo JL, Kamata H, Karin M. IKK/NF-κB signaling: balancing life and death - a new approach to cancer therapy. J Clin Invest 2005;115:2625-32.
39. Krishnan AV, Peehl DM, Feldman D. The role of vitamin D in prostate cancer. Recent Results Cancer Res 2003;164:205-21.
40. Krishnan AV, Peehl DM, Feldman D. Inhibition of prostate cancer growth by vitamin D: regulation of target gene expression. J Cell Biochem 2003;88:363-71.
41. Vijayakumar S, Mehta RR, Boerner PS, et al. Clinical trials involving vitamin D analogs in prostate cancer. Cancer J 2005;11:362-73.
42. Price DK, Franks ME, Figg WD. Genetic variations in the vitamin D receptor, androgen receptor, and enzymes that regulate androgen metabolism. J Urol 2004;171:S45-9.
43. 3-inducible catabolism of vitamin D metabolites in mouse intestine. Am J Physiol 1990;258:G557-63.
44. Beer TM, Myrthue A. Calcitrol in cancer treatment: from the lab to the clinic. Mol Cancer Ther 2004;3:373-81.
45. Masuda S, Jones G. Promise of vitamin D analogues in the treatment of hyperproliferative conditions. Mol Cancer Ther 2006;5:797-808.
46. 3 in lipiodol: pilot study in patients with hepatocellular carcinoma. Int J Oncol 2002;21:901-6.
47. Dhar SK, Lynn BC, Daosukho C, St Clair DK. Identification of nucleophosmin as an NF-κB co-activator for the induction of the human sod2 gene. J Biol Chem 2004;279:28209-19.
48. 3 and its analogs: physiologic and therapeutic implications for dendritic cell function. J Biol Chem 2003;278:49378-85.
49. Dong X, Lutz W, Schroeder TM, et al. Regulation of relB in dendritic cells by means of modulated association of vitamin D receptor and histone deacetylase 3 with the promoter. Proc Natl Acad Sci U S A 2005;102:16007-12.
50. Brown JM, Attardi LD. The role of apoptosis in cancer development and treatment response. Nat Rev Cancer 2005;5:231-7.